

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Crovalimab for treating paroxysmal nocturnal
haemoglobinuria [ID6140]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

(when no draft guidance was issued)

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

The following were identified as potential equality issues during the scoping process:

- Age and pregnancy were highlighted as protected characteristics. Inequalities may arise if different recommendations are made for children and pregnant women. It was noted that there will not be trial data for children and pregnant women at this stage.
- All paroxysmal nocturnal haemoglobinuria patients in England can access the two paroxysmal nocturnal haemoglobinuria centres for management of paroxysmal nocturnal haemoglobinuria (Leeds and London).

The Lead team considered the equality issues during the appraisal process. Crovalimab was recommended within its full marketing authorisation.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Crovalimab was recommended within its full marketing authorisation.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Equality discussions have not been described in the final draft guidance.
Cost comparisons include only limited discussion of issues.

Approved by Associate Director (name): Ross Dent

Date: 12/09/2024